Myricx Bio
Biotechnology company developing next-generation antibody-drug conjugates (ADCs) for cancer therapy, using innovative linker-payload technologies to improve efficacy and safety.
Website
https://www.myricx.comLocation
London, United Kingdom
Founded
2019
Investors
2
Categories
therapeutics, biotech, oncology, adc, antibody-drug-conjugates
Notes
Myricx Bio is a biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for cancer therapy. ADCs combine the targeting precision of antibodies with the cytotoxic power of small molecule drugs, enabling selective destruction of cancer cells while minimizing damage to healthy tissue.
The company's platform focuses on novel linker-payload technologies that improve the stability, efficacy, and safety profile of ADCs compared to earlier generations of these therapeutics.
Team
- Information on leadership team pending further research
Additional Research Findings
- Founded in 2019
- Headquarters in London, United Kingdom
- Backed by Novo Holdings
- Antibody-drug conjugate technology platform
- Focus on oncology applications
- Novel linker-payload technologies
- Part of growing ADC therapeutic market
- UK life sciences ecosystem
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Novo Holdings | Hellerup, Denmark | biotech-focused | seedseries-a+3 | 13 |
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |